Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase IV, multicenter study to evaluate the correlation of the overall objective response according to RECIST criteria v1.1. assessed by conventional imaging techniques, the morphologic response by CT and pathologic response after the resectability of liver metastases secondary to colorectal cancer treated with bevacizumab in combination with XELOX

Trial Profile

Phase IV, multicenter study to evaluate the correlation of the overall objective response according to RECIST criteria v1.1. assessed by conventional imaging techniques, the morphologic response by CT and pathologic response after the resectability of liver metastases secondary to colorectal cancer treated with bevacizumab in combination with XELOX

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 13 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Oxaliplatin (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms AVAMET
  • Most Recent Events

    • 12 Sep 2017 Status changed from recruiting to completed, as per an abstract presented at the 42nd European Society for Medical Oncology Congress
    • 12 Sep 2017 Results presented at the 42nd European Society for Medical Oncology Congress
    • 23 May 2012 New trial record
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top